Search

Your search keyword '"Joerg Kraus"' showing total 2 results
Start Over Author "Joerg Kraus" Journal plos one
2 results on '"Joerg Kraus"'

1. Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.

Author

Andrea Harrer, Georg Pilz, Max Einhaeupl, Katrin Oppermann, Wolfgang Hitzl, Peter Wipfler, Johann Sellner, Stefan Golaszewski, Shahrzad Afazel, Elisabeth Haschke-Becher, Eugen Trinka, and Joerg Kraus

Subjects
Medicine, Science
Abstract

Natalizumab is an effective monoclonal antibody therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS) and interferes with immune cell migration into the central nervous system by blocking the α(4) subunit of very-late activation antigen-4 (VLA-4). Although well tolerated and very effective, some patients still suffer from relapses in spite of natalizumab therapy or from unwanted side effects like progressive multifocal leukoencephalopathy (PML). In search of a routine-qualified biomarker on the effectiveness of natalizumab therapy we applied flow cytometry and analyzed natalizumab binding to α(4) and α(4) integrin surface levels on T-cells, B-cells, natural killer (NK) cells, and NKT cells from 26 RRMS patients under up to 72 weeks of therapy. Four-weekly infusions of natalizumab resulted in a significant and sustained increase of lymphocyte-bound natalizumab (p

Published
2012
Full Text
View/download PDF

2. Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis

Author

Georg Pilz, Andrea Harrer, Joerg Kraus, Eugen Trinka, Stefan Golaszewski, Wolfgang Hitzl, Shahrzad Afazel, Katrin Oppermann, Max Einhaeupl, Elisabeth Haschke-Becher, Peter Wipfler, and Johann Sellner

Subjects
Adult, Male, Time Factors, Integrin alpha4, lcsh:Medicine, Antibodies, Monoclonal, Humanized, Flow cytometry, Natalizumab, Immune system, Multiple Sclerosis, Relapsing-Remitting, medicine, Humans, lcsh:Science, Monoclonal antibody therapy, Multidisciplinary, medicine.diagnostic_test, business.industry, Progressive multifocal leukoencephalopathy, Multiple sclerosis, lcsh:R, Natural killer T cell, medicine.disease, Flow Cytometry, Antibodies, Neutralizing, Lymphocyte Subsets, Neurology, Immunology, Biomarker (medicine), Medicine, lcsh:Q, Female, Clinical Immunology, business, medicine.drug, Research Article
Abstract

Natalizumab is an effective monoclonal antibody therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS) and interferes with immune cell migration into the central nervous system by blocking the α(4) subunit of very-late activation antigen-4 (VLA-4). Although well tolerated and very effective, some patients still suffer from relapses in spite of natalizumab therapy or from unwanted side effects like progressive multifocal leukoencephalopathy (PML). In search of a routine-qualified biomarker on the effectiveness of natalizumab therapy we applied flow cytometry and analyzed natalizumab binding to α(4) and α(4) integrin surface levels on T-cells, B-cells, natural killer (NK) cells, and NKT cells from 26 RRMS patients under up to 72 weeks of therapy. Four-weekly infusions of natalizumab resulted in a significant and sustained increase of lymphocyte-bound natalizumab (p

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results